Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Arcus Biosciences presented new data from its ARC-20 platform study evaluating casdatifan in various treatment lines for clear cell renal cell carcinoma (ccRCC). Key results included a 50% confirmed objective response rate (cORR) for the first-line casdatifan plus zimberelimab combination and a 14.5-month median progression-free survival for the second-line combination with cabozantinib.
Kinetic Seas announced the commercial availability of three foundational AI software platforms: MaluDB, MaluOS, and MaluMail. These products provide enterprise infrastructure for building and deploying scalable agentic and generative AI applications under a dual open-source and enterprise subscription model.
Mount Logan Capital Signs $4.6M M&A Deal with Alternative Fund Advisors, LLC
Mount Logan Management, LLC, a subsidiary of Mount Logan Capital Inc., entered into a definitive agreement to acquire the management rights and related assets of the AFA Asset Based Lending Fund (AMCLX) from Alternative Fund Advisors, LLC. Mount Logan will pay up to $4.6 million in cash and deferred installments, plus 40% of management and incentive fees for five years, to succeed AFA as the fund's investment adviser.
Value
$4.6M
Counterparty
Alternative Fund Advisors, LLC
Term
5 years
“This is a significant milestone in the build-out of Mount Logan's evergreen credit platform and reflects our continued discipline in acquiring permanent and semi-permanent capital vehicles. The Fund broadens MLM's core products, extends our distribution reach in the private wealth channel, and is highly complementary to our Opportunistic Credit Interval Fund. It also provides a differentiated, institutionally managed asset-based lending strategy that leverages the credit sourcing and underwriting capabilities of the broader Mount Logan and BC Partners Credit platform.”
XWELL, Inc. received a deficiency notice from Nasdaq on October 7, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has 180 calendar days, or until April 5, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. XWELL is monitoring the situation and considering options, including a potential reverse stock split, to address the deficiency.
Launch Two Acquisition M&A Deal with NuCube Energy, Inc.
Launch Two Acquisition Corp. entered into an amendment to its existing business combination agreement with NuCube Energy, Inc., extending the deal's outside closing date to January 7, 2027. The amendment also permits NuCube to conduct interim financing through the issuance of Series A-4 Preferred Stock and increases the post-closing employee incentive plan share reserve to 12.5%.
Prudential Financial Divestiture to CNP Assurances Group for $4.03B
Prudential Financial has entered into definitive agreements to sell its equity interests in Prudential of Brazil and Prudential of Mexico to CNP Assurances for approximately $4.025 billion in cash. The transaction is part of Prudential's strategy to exit emerging markets and refocus capital on its core growth opportunities in the U.S., Japan, and select European markets.
Maximus Signs $660M M&A Deal with Agile Defense, LLC
Maximus, Inc. has entered into a definitive agreement to acquire Agile Defense, LLC for $660 million in cash, plus up to $50 million in contingent earnout payments. The acquisition aims to expand Maximus' presence in the defense and national security markets by adding specialized cybersecurity, AI, and digital transformation capabilities. The deal is expected to close in the first quarter of fiscal year 2027, subject to regulatory approvals.
Hertz Global Holdings Partnership with Cohen Private Ventures Worth $80.9M
Hertz entered into a joint venture arrangement for its Oro Mobility business, with a consortium of investors purchasing a 50% voting interest and 15.86% economic interest in the JV entity for $80.89 million. Hertz will retain majority economic ownership and serve as a fleet and corporate services partner to Oro, which operates approximately 45,000 vehicles across U.S. mobility markets. Concurrently, Hertz repurchased $51.1 million of its 2029 exchangeable notes from the investors at a 60% discount to par.
Value
$80.9M
Counterparty
Cohen Private Ventures, Certares Opportunities LLC, and Knighthead Capital Management, LLC
Iridium Communications M&A Deal with Rocket Lab Corporation
Iridium provided a status update on its pending acquisition by Rocket Lab, noting that stockholders approved the transaction on September 24, 2026, with 99.6% of votes cast in favor. The deal is expected to close by mid-2027, following the company's recent completion of its acquisition of Aireon.
Counterparty
Rocket Lab Corporation
“Last month’s stockholder approval for Rocket Lab’s acquisition of Iridium was an important milestone in creating a next generation space powerhouse.”
Matt Desch, CEO, Iridium
“The combination of these two leading space companies will unlock new innovation in the space industry and accelerate our growth in critical space-based missions.”
Odyssey Therapeutics announced positive Phase 2a results for its oral RIPK2 inhibitor, OD-001, in patients with moderate-to-severe ulcerative colitis. The trial met its primary endpoint with a 27% clinical remission rate at the 20 mg BID dose at Week 12, showing significant correlation between clinical efficacy and inflammatory biomarkers.
Quoin Pharmaceuticals announced the publication of a peer-reviewed case report detailing 21 months of compassionate use treatment with QRX003 in a pediatric Netherton Syndrome patient, showing an improvement from severe to clear skin. The company also reaffirmed that its ongoing Phase 2/3 study of QRX003 expects to complete recruitment by the end of 2026 with topline data anticipated in Q2 2027.
Rapport Therapeutics announced positive topline results from its Phase 2 trial of RAP-219 for the treatment of bipolar mania, meeting the primary endpoint with a statistically significant 3.1-point placebo-adjusted improvement in the YMRS total score. The drug was well-tolerated with no serious adverse events, establishing clinical proof-of-concept for its novel TARP g8-selective mechanism. The company plans to progress RAP-219 into Phase 3 trials for bipolar mania in the second half of 2027.
BioAtla, Inc. entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville, establishing a facility to sell up to $40.0 million of common stock at the company's option. Shares will be sold at 97% of the lowest daily VWAP over a three-day pricing period following an advance notice. As consideration, the company agreed to pay a $500,000 commitment fee, partially settled through the issuance of warrants for 182,110 shares.
Silgan Holdings Signs $1.02B M&A Deal with Trivium Packaging B.V.
Silgan Holdings entered into a definitive agreement to form a partnership with AIP, LLC (A-VL Investor) to combine Silgan's Metal Containers and Closures Business with Trivium Packaging B.V. Silgan will contribute its business for a 60% stake in the new entity (MetalCo) and a $2.263 billion cash distribution, while A-VL Investor will contribute $1.025 billion for a 40% stake.
Treasure Global M&A Deal with Platinum Recognition Sdn. Bhd.
Treasure Global Inc (TGL), through its subsidiary Tadaa Capital Sdn. Bhd., entered into a definitive agreement to acquire 100% of Platinum Recognition Sdn. Bhd. (PRSB), a Malaysian budget hotel operator. The purchase price is RM2,400,000, consisting of a 10% cash deposit and 90% payable through an escrow realization scheme involving the issuance of TGL common stock.
Tessera Defense & Homeland Security M&A Deal with Mandragola Ltd.
Tessera Defense and Homeland Security Inc. issued 6,529,494 restricted shares of common stock to Mandragola Ltd. following the cashless exercise of warrants. These warrants were originally issued in April 2026 as part of the consideration for Tessera's acquisition of a 60% interest in Dr. Frucht Systems Ltd. (DFSL).
Venu Holding Corp completed the second and final tranche of a $10 million equity investment from Aramark, raising $5.01 million through the sale of 334 shares of Series B Preferred Stock. Additionally, the company announced that William Hodgson has stepped down as President, with his responsibilities being assumed by the existing management team.
Tradeweb Markets Signs $1.97B M&A Deal with Trumid Holdings, LLC
Tradeweb Markets Inc. has entered into a definitive agreement to acquire electronic credit trading marketplace Trumid for approximately $1.97 billion. The deal combines Tradeweb's multi-asset platform with Trumid's innovative credit protocols to expand capabilities into the full bond lifecycle, including new issue origination and secondary trading.
Value
$1.97B
Counterparty
Trumid Holdings, LLC
“This acquisition represents an important step forward in our ambition to make credit markets more efficient and provide clients with smarter ways to access liquidity. We believe U.S. credit represents a significant long-term growth opportunity, particularly as the market continues to embrace electronic execution and as clients seek increasingly sophisticated solutions to navigate liquidity and achieve better outcomes.”
Billy Hult, CEO of Tradeweb
“We look forward to incorporating our innovative protocols, agile technology, and collaborative client-centric approach to product development into Tradeweb’s global footprint and client network. Our teams share dual passions for technology and client experience.”
LXP Industrial Trust M&A Deal with Leopard REIT LLC
LXP Industrial Trust provided a status update on its pending merger with Leopard REIT LLC, specifically addressing shareholder litigation and demand letters alleging disclosure deficiencies in the proxy statement. To avoid potential delays to the merger and minimize litigation costs, the company has voluntarily supplemented its definitive proxy statement ahead of the special meeting of shareholders scheduled for October 26, 2026.
Stardust Power Inc. received a Staff Delisting Determination from Nasdaq on October 15, 2026, after its common stock closed at $0.10 or less for ten consecutive trading days. Nasdaq intends to suspend trading and delist the company's securities on October 23, 2026, though the company may appeal the decision to the Nasdaq Hearings Panel.
TCGX Acquisition Corp. II consummated its initial public offering (IPO) of 10,000,000 Class A ordinary shares at $10.00 per share, raising $100 million in gross proceeds. Simultaneously, the company raised an additional $4.5 million through a private placement of 450,000 shares to its sponsor, TCGX Sponsor II, LLC.
3M Company has entered into an expanded strategic commercial relationship with Amazon for optical connectivity and other Data Center products. As part of the deal, 3M issued a warrant to Amazon to purchase up to 3.16 million shares at $164.89 per share, with vesting tied to Amazon making up to $6 billion in cumulative payments for 3M products.
The AES Corporation received unconditional merger approval from the European Commission and a favorable declaratory ruling from the New York Public Service Commission regarding its pending acquisition by Horizon Parent, L.P. The transaction, originally announced in March 2026, will result in AES being jointly owned by Global Infrastructure Management, LLC and EQT Infrastructure VI. The deal remains subject to additional regulatory approvals and customary closing conditions.
VenHub Global announced that its existing Equity Line of Credit (ELOC) has been assigned from Euphoria Capital to Tunim Stone Capital, LLC. Under the Assignment and Assumption Agreement, Tunim Stone Capital assumes all rights and obligations of the ELOC, while Euphoria Capital retains 500,000 commitment shares and associated registration rights.
Vivos Therapeutics Signs $12M M&A Deal with SOD Sciences, Inc.
Vivos Therapeutics completed the acquisition of an 11% equity stake in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia early-warning test. The transaction was valued at $12 million, paid via the issuance of 12,000 shares of Series C Convertible Preferred Stock, and is expected to add over $10 million to Vivos' stockholders' equity.
Value
$12M
Counterparty
SOD Sciences, Inc.
“Today Vivos became more than a healthcare company just treating sleep apnea. We expect this transaction to add more than $10 million to our stockholders’ equity, and we now own half of a test designed to identify patients whose sleep apnea may be contributing to chronic disease.”
R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos
Service Properties Trust (SVC) completed the sale of three hotels for an aggregate sales price of $19.0 million on October 15, 2026. The transaction was executed pursuant to a previously entered purchase and sale agreement and was reported as a significant disposition of assets.
Eva Live Inc. filed a prospectus supplement to facilitate an existing equity purchase agreement with Hudson Global Ventures, LLC. The agreement allows the company to sell up to 5,000,000 shares of common stock for an aggregate price of up to $10 million. Additionally, the company issued a warrant to the investor for 275,000 shares at an exercise price of $0.01 per share.
Curis, Inc. entered into a securities purchase agreement to raise approximately $8.5 million through the sale of 16,666,680 shares of common stock (or pre-funded warrants) and accompanying common warrants at a combined price of $0.51 per share. The company intends to use the proceeds to fund research and development activities, specifically to support operations through its initial Chronic Lymphocytic Leukemia (CLL) data readout expected in December 2026.
Medtronic plc has completed the separation of its diabetes business, MiniMed Group, Inc., into an independent publicly traded company via a tax-free exchange offer. Medtronic exchanged its remaining 252,813,348 shares of MiniMed common stock for outstanding Medtronic ordinary shares in an offer that was 5.4x oversubscribed.
Curaleaf Holdings M&A Deal with Aurora Cannabis Inc.
Curaleaf Holdings, Inc. responded to Aurora Cannabis Inc.'s rejection of its enhanced acquisition proposal, challenging the Aurora Board's refusal to grant due diligence access. Curaleaf noted its offer represents an 86% premium to Aurora's unaffected 30-day VWAP and criticized Aurora for providing diligence access to other unnamed parties while obstructing Curaleaf's binding offer.